BIOMAT Database Logo BIOMAT Database Logo

Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. 2010

Li-Xuan Sang, and Bing Chang, and Wen-Liang Zhang, and Xiao-Mei Wu, and Xiao-Hang Li, and Min Jiang
Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang 110001, Liaoning Province, China. sanglixuan2008@sohu.com

OBJECTIVE To evaluate the induction of remission and maintenance effects of probiotics for ulcerative colitis. METHODS Information was retrieved from MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The induction of remission and promotion of maintenance were compared between probiotics treatment and non-probiotics treatment in ulcerative colitis. RESULTS Thirteen randomized controlled studies met the selection criteria. Seven studies evaluated the remission rate, and eight studies estimated the recurrence rate; two studies evaluated both remission and recurrence rates. Compared with the non-probiotics group, the remission rate for ulcerative colitis patients who received probiotics was 1.35 (95% CI: 0.98-1.85). Compared with the placebo group, the remission rate of ulcerative colitis who received probiotics was 2.00 (95% CI: 1.35-2.96). During the course of treatment, in patients who received probiotics for less than 12 mo compared with the group treated by non-probiotics, the remission rate of ulcerative colitis was 1.36 (95% CI: 1.07-1.73). Compared with the non-probiotics group, the recurrence rate of ulcerative colitis patients who received probiotics was 0.69 (95% CI: 2.47-1.01). In the mild to moderate group who received probiotics, compared to the group who did not receive probiotics, the recurrence rate was 0.25 (95% CI: 0.12-0.51). The group who received Bifidobacterium bifidum treatment had a recurrence rate of 0.25 (95% CI: 0.12-0.50) compared with the non-probiotics group. CONCLUSIONS Probiotic treatment was more effective than placebo in maintaining remission in ulcerative colitis.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003093 Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN. Colitis Gravis,Idiopathic Proctocolitis,Inflammatory Bowel Disease, Ulcerative Colitis Type,Ulcerative Colitis
D004724 Endoscopy Procedures of applying ENDOSCOPES for disease diagnosis and treatment. Endoscopy involves passing an optical instrument through a small incision in the skin i.e., percutaneous; or through a natural orifice and along natural body pathways such as the digestive tract; and/or through an incision in the wall of a tubular structure or organ, i.e. transluminal, to examine or perform surgery on the interior parts of the body. Endoscopic Surgical Procedures,Surgical Procedures, Endoscopic,Endoscopic Surgical Procedure,Endoscopy, Surgical,Surgical Endoscopy,Surgical Procedure, Endoscopic,Procedure, Endoscopic Surgical,Procedures, Endoscopic Surgical
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001644 Bifidobacterium A rod-shaped, gram-positive, non-acid-fast, non-spore-forming, non-motile bacterium that is a genus of the family Bifidobacteriaceae, order Bifidobacteriales, class ACTINOBACTERIA. It inhabits the intestines and feces of humans as well as the human vagina.
D012306 Risk The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome. Relative Risk,Relative Risks,Risk, Relative,Risks,Risks, Relative
D015233 Models, Statistical Statistical formulations or analyses which, when applied to data and found to fit the data, are then used to verify the assumptions and parameters used in the analysis. Examples of statistical models are the linear model, binomial model, polynomial model, two-parameter model, etc. Probabilistic Models,Statistical Models,Two-Parameter Models,Model, Statistical,Models, Binomial,Models, Polynomial,Statistical Model,Binomial Model,Binomial Models,Model, Binomial,Model, Polynomial,Model, Probabilistic,Model, Two-Parameter,Models, Probabilistic,Models, Two-Parameter,Polynomial Model,Polynomial Models,Probabilistic Model,Two Parameter Models,Two-Parameter Model

Related Publications

Li-Xuan Sang, and Bing Chang, and Wen-Liang Zhang, and Xiao-Mei Wu, and Xiao-Hang Li, and Min Jiang
Probiotics for maintenance of remission in ulcerative colitis.
March 2020, The Cochrane database of systematic reviews,
Li-Xuan Sang, and Bing Chang, and Wen-Liang Zhang, and Xiao-Mei Wu, and Xiao-Hang Li, and Min Jiang
Probiotics for maintenance of remission in ulcerative colitis.
December 2011, The Cochrane database of systematic reviews,
Li-Xuan Sang, and Bing Chang, and Wen-Liang Zhang, and Xiao-Mei Wu, and Xiao-Hang Li, and Min Jiang
Probiotics for induction of remission in ulcerative colitis.
October 2007, The Cochrane database of systematic reviews,
Li-Xuan Sang, and Bing Chang, and Wen-Liang Zhang, and Xiao-Mei Wu, and Xiao-Hang Li, and Min Jiang
Probiotics for induction of remission in ulcerative colitis.
March 2020, The Cochrane database of systematic reviews,
Li-Xuan Sang, and Bing Chang, and Wen-Liang Zhang, and Xiao-Mei Wu, and Xiao-Hang Li, and Min Jiang
[Induction and maintenance of remission in ulcerative colitis].
October 2004, Gastroenterologie clinique et biologique,
Li-Xuan Sang, and Bing Chang, and Wen-Liang Zhang, and Xiao-Mei Wu, and Xiao-Hang Li, and Min Jiang
Antibiotics for induction and maintenance of remission in ulcerative colitis: systematic review and meta-analysis.
October 2021, Expert review of gastroenterology & hepatology,
Li-Xuan Sang, and Bing Chang, and Wen-Liang Zhang, and Xiao-Mei Wu, and Xiao-Hang Li, and Min Jiang
Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis.
May 2015, Inflammatory bowel diseases,
Li-Xuan Sang, and Bing Chang, and Wen-Liang Zhang, and Xiao-Mei Wu, and Xiao-Hang Li, and Min Jiang
Comparison of maintenance effect of probiotics and aminosalicylates on ulcerative colitis: A meta-analysis of randomized controlled trials.
March 2016, Chronic diseases and translational medicine,
Li-Xuan Sang, and Bing Chang, and Wen-Liang Zhang, and Xiao-Mei Wu, and Xiao-Hang Li, and Min Jiang
Infliximab for ulcerative colitis induction of remission and maintenance therapy.
January 2007, Gastroenterology & hepatology,
Li-Xuan Sang, and Bing Chang, and Wen-Liang Zhang, and Xiao-Mei Wu, and Xiao-Hang Li, and Min Jiang
Vedolizumab for induction and maintenance of remission in ulcerative colitis.
August 2014, The Cochrane database of systematic reviews,
Copied contents to your clipboard!